Autolus Therapeutics (AUTL) Set to Release Quarterly Earnings on Tuesday

Autolus Therapeutics (NASDAQ:AUTL) is projected to announce its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect Autolus Therapeutics to announce earnings of ($0.21) per share and revenue of $39.54 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:30 AM ET.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.06. The company had revenue of $45.69 million for the quarter, compared to analyst estimates of $38.56 million. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. On average, analysts expect Autolus Therapeutics to post ($0.76) EPS for the current fiscal year and ($0.62) EPS for the next fiscal year.

Autolus Therapeutics Trading Down 0.4%

NASDAQ AUTL traded down $0.01 during trading on Tuesday, hitting $1.42. The stock had a trading volume of 1,740,011 shares, compared to its average volume of 1,803,574. Autolus Therapeutics has a one year low of $1.18 and a one year high of $2.58. The stock has a 50 day simple moving average of $1.89 and a 200 day simple moving average of $1.67. The stock has a market capitalization of $376.62 million, a price-to-earnings ratio of -1.33 and a beta of 2.15. The company has a debt-to-equity ratio of 1.04, a quick ratio of 4.40 and a current ratio of 4.89.

Wall Street Analyst Weigh In

AUTL has been the topic of several recent analyst reports. HC Wainwright assumed coverage on Autolus Therapeutics in a report on Monday. They issued a “buy” rating on the stock. Wall Street Zen upgraded Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Finally, Weiss Ratings raised Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for cancer. The company’s approach is designed to engineer T cells to recognize and eliminate malignant cells while incorporating features intended to improve activity, persistence and safety.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States under the brand name Aucatzyl. It is used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.